Publication details

Úskalí léčby chronické myeloidní leukemie dasatinibem – plicní arteriální hypertenze jako vzácná komplikace

Title in English Pitfalls of treating chronic myeloid leukaemia with dasatinib – pulmonary arterial hypertension as a rare complication
Authors

ČIČÁTKOVÁ Petra ŽÁČKOVÁ Daniela KVETKOVÁ Anežka HORŇÁK Tomáš SEMERÁD Lukáš

Year of publication 2021
Type Article in Periodical
Magazine / Source Transfuze a hematologie dnes
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.prolekare.cz/casopisy/transfuze-hematologie-dnes/2021-2-21/uskali-lecby-chronicke-myeloidni-leukemie-dasatinibem-plicni-arterialni-hypertenze-jako-vzacna-komplikace-127610
Doi http://dx.doi.org/10.48095/cctahd20211
Keywords chronic myeloid leukaemia – dasatinib – pleural effusions – pulmonary arterial hypertension
Description Dasatinib is a potent tyrosine kinase inhibitor of not only Bcr-Abl1, but also of the Src kinase family, c-kit and PDGFR-b. This “offtarget” effect is the probable cause of pleural effusions, which complicate dasatinib therapy in about one third of patients. The following case report describes a chronic myeloid leukaemia patient with not only recurrent pleural effusions but also pulmonary arterial hypertension as a serious adverse event leading to dasatinib discontinuation.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info